GlassScriptPhysician profile
Julia M Gross
NPI 1114271970
$8,074.41
in general payments reported to CMS, 2019-2025
50 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,098 · 2022: $1,118 · 2023: $1,806 · 2024: $2,053 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,859.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,319.15 | 2021-2025 | |
| Bausch Health US, LLC | $969.54 | 2021-2025 | Aplenzin, Wellbutrin |
| Novo Nordisk INC | $923.77 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $486.29 | 2021-2025 | Mounjaro, Zepbound, Olumiant |
| Astrazeneca Pharmaceuticals LP | $411.81 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Axsome Therapeutics, INC. | $305.39 | 2023-2025 | Auvelity, Symbravo |
| Teva Pharmaceuticals USA, INC. | $304.09 | 2024-2025 | Austedo Xr, Uzedy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.52 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $222.20 | 2023-2025 | |
| Corium, LLC | $209.08 | 2023-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $201.92 | 2024-2025 | Spravato |
| Amgen INC. | $194.59 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.19 | 2021-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $182.72 | 2021-2025 | Trintellix |
| Astellas Pharma US INC | $175.49 | 2021-2025 | Veozah |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.